¶¶Òõ¶ÌÊÓƵ

I am a clinical epidemiologist with over 15 years expertise in fracture epidemiology. Broadly my research interests are in determining the adverse outcomes associated with osteoporotic fracture and the effectiveness and safety of osteoporosis medicines in real world settings. My PhD work demonstrated high risk of long-term adverse events associated with osteoporotic fracture, the contribution of subsequent fracture to premature mortality (Bliuc D. et al JAMA 2009) and demonstrated the burden of adverse events in low trauma fracture with normal bone mineral density (Bliuc D et al Journal of Bone and Mineral Research 2015). This work has contributed to the development of fracture prevention guidelines. My postdoctoral research has provided evidence of the role of nitrogen-bisphosphonates on mortality risk reduction (Bliuc D et al Osteoporosis International 2019) and demonstrated that bone loss reduction is a plausible mechanism for their survival benefit (Bliuc D et al Journal of Bone and Mineral Research 2019). Currently, my research focuses on the importance of multimorbidity in osteoporosis medicines prescription (Bliuc D et al PloS Medicine 2023) as well as the impact of quality of life to post-fracture adverse outcomes ( Bliuc D et al JAMA Network Open 2024).

Ìý

I have experience in experimental design and data analysis, including modelling complex longitudinal data from population-based cohorts as well as cohorts based on linkage of administrative datasets.